Hemodynamic response to treatment and outcome in pulmonary hypertension associated with interstitial lung disease versus pulmonary arterial hypertension in systemic sclerosis

EULAR ^® 2019

Systemic Sclerosis-Associated Interstitial Lung Disease

Distler et al. 2019. Nintedanib reduced decline in forced vital capacity across subgroups of patients with systemic sclerosis-associated interstitial lung disease: Data from the SENSCIS trial. Oral presentation presented at: EULAR 2019 Congress; 12–15 June 2019; Madrid, Spain.

Systemic Sclerosis

Disease frequency, patient characteristics, comorbidity outcomes and immunosuppressive therapy in systemic sclerosis and systemic sclerosis-associated interstitial lung disease: a US cohort study

Rheumatology (Oxford)

Li Q, Wallace L, Patnaik P, Alves M, Gahlemann M, Kohlbrenner V, Raabe C, Wang JR, Garry EM

doi: 10.1093/rheumatology/keaa547

Systemic SclerosisFurther Publications Rheumatology

Outcome measurement instrument selection for lung physiology in systemic sclerosis associated interstitial lung disease: A systematic review using the OMERACT filter 2.1 process

Semin Arthritis Rheum

Roofeh D, Barratt SL, Wells AU, Kawano-Dourado L, Tashkin D, Strand V, Seibold J, Proudman S, Brown KK, Dellaripa PF, Doyle T, Leonard T, Matteson EL, Oddis CV, Solomon JJ, Sparks JA, Vassallo R, Maxwell L, Beaton D, Christensen R, Townsend W, Khanna D

doi: 10.1016/j.semarthrit.2021.08.001

Further Publications Rheumatology

Serum markers of pulmonary epithelial damage in systemic sclerosis-associated interstitial lung disease and disease progression

Respirology

Stock CJW, Hoyles RK, Daccord C, Kokosi M, Visca D, De Lauretis A, Alfieri V, Kouranos V, Margaritopoulos G, George PM, Molyneaux PL, Chua F, Maher TM, Abraham DJ, Ong V, Donovan J, Sestini P, Denton CP, Wells AU, Renzoni EA

doi: 10.1111/resp.13988

COMMENTED

Systemic Sclerosis

Early treatment with ambrisentan of mildly elevated mean pulmonary arterial pressure associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group study (EDITA study)

★ 3 Recommended and commented by Dr Heino Prillwitz, Faculty Member

Arthritis Res Ther.

Pan Z, Marra AM, Benjamin N, Eichstaedt CA, Blank N, Bossone E, Cittadini A, Coghlan G, Denton CP, Distler O, Egenlauf B, Fischer C, Harutyunova S, Xanthouli P, Lorenz HM, Grünig E

doi: 10.1186/s13075-019-1981-0.

Systemic Sclerosis

Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: post hoc analysis

Ann Rheum Dis.

Kuwana M, Blair C, Takahashi T, Langley J, Coghlan JG

doi: 10.1136/annrheumdis-2019-216274.

Systemic Sclerosis

Single-cell analysis reveals fibroblast heterogeneity and myofibroblasts in systemic sclerosis-associated interstitial lung disease

Ann Rheum Dis.

Valenzi E, Bulik M, Tabib T, Morse C, Sembrat J, Trejo Bittar H, Rojas M, Lafyatis R

doi: 10.1136/annrheumdis-2018-214865.

RECOMMENDED

Systemic Sclerosis

Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial

★ 2 Recommended by Dr Martin Frey, Faculty Member

Ann Rheum Dis

Seibold JR, Maher TM, Highland KB, Assassi S, Azuma A, Hummers LK, Costabel U, von Wangenheim U, Kohlbrenner V, Gahlemann M, Alves M, Distler O, SENSCIS trial investigators.

doi: 10.1136/annrheumdis-2020-217331

Systemic Sclerosis

Biomarkers in systemic sclerosis-associated interstitial lung disease: review of the literature

Rheumatology (Oxford).

Bonhomme O, André B, Gester F, de Seny D, Moermans C, Struman I, Louis R, Malaise M, Guiot J

doi: 10.1093/rheumatology/

Related content

Systemic Sclerosis-Associated Interstitial Lung Disease

Disease frequency, patient characteristics, comorbidity outcomes and immunosuppressive therapy in systemic sclerosis and systemic sclerosis-associated interstitial lung disease: a US cohort study

Outcome measurement instrument selection for lung physiology in systemic sclerosis associated interstitial lung disease: A systematic review using the OMERACT filter 2.1 process

Serum markers of pulmonary epithelial damage in systemic sclerosis-associated interstitial lung disease and disease progression

Early treatment with ambrisentan of mildly elevated mean pulmonary arterial pressure associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group study (EDITA study)

Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: post hoc analysis

Single-cell analysis reveals fibroblast heterogeneity and myofibroblasts in systemic sclerosis-associated interstitial lung disease

Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial

Biomarkers in systemic sclerosis-associated interstitial lung disease: review of the literature